ClinicalTrials.gg
CompletedNCT01144949Updated Aug 11, 2014Results posted

Study of Silodosin to Facilitate Passage of Urinary Stones

A Phase 2 interventional study of silodosin and placebo in Ureteral Calculi, Kidney Stones and Urolithiasis, sponsored by Watson Pharmaceuticals. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-11.

Sponsored by Watson Pharmaceuticals (part of AbbVie) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
239
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Ureteral Calculi with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Ureteral Calculi · United States.

Enrollment
Largest of 13
239 · median 74
Started
2010
the only one that year
Phase 2
Only one
of the 13
Registered
4th of 13
by date
Lead sponsor
1 of 13
Watson Pharmaceuticals

Among the 13 studies in Ureteral Calculi with a site in United States, this one has the largest enrollment, is the only one that started in 2010, is the only one in phase 2, and was the 4th registered.

Ureteral Calculi

51 studies on the registry are indexed under Ureteral Calculi; 15 are open to participants now.

Browse Ureteral Calculi studies →

Open to participants now

2 of the 13 studies in Ureteral Calculi with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Ureteral Calculi studies recruiting now, 5 (45%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Ureteral Calculi with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.

03

Conditions studied

  • Ureteral Calculi
  • Kidney Stones
  • Urolithiasis

Keywords

  • ureteral calculi
  • renal colic
  • ureteral stones
  • kidney stones
  • medical expulsive therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age or older
  • Male or a non-pregnant, non-lactating female using adequate means of , if not menopausal
  • Have radiopaque unilateral ureteral calculus ≥4mm and ≤10mm in any location of the ureter

Exclusion criteria

Exclusion Criteria:

  • Multiple ureteral calculi, or a solitary kidney, or renal colic, or a non-opaque calculus, or active urinary tract infection, or severe hydronephrosis
  • History of previous ureteral surgery or ureteral stricture on affected side
  • History of any of the following conditions: myasthenia gravis, myopathy, spina bifida, spinal cord injury, autonomic nervous system disorder, fibromyalgia, breast cancer
  • Moderate to severe renal impairment or severe liver insufficiency
  • History of significant postural hypotension
  • Is receiving medication(s) which preclude safe participation in the study or that may produce a confounding effect on the variables under study
  • History of allergy to alpha-blockers or oxycodone
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
239 participants (actual)

Study arms

  • Active comparator
    silodsosin

    Drug: silodosin

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

  • one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks

  • Drugplacebo

    one placebo capsule orally, once daily, with food for up to 4 weeks

06

What researchers measure

Primary outcomes

  1. Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.

    The primary efficacy variable is the occurrence of spontaneous distal stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes only those stones located in the distal ureter.

    Time frame: 4 weeks

  2. Spontaneous Stone Passage (All Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.

    The primary efficacy variable is the occurrence of spontaneous stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes all ureteral stones, regardless of location in the ureter.

    Time frame: 4 weeks

Secondary outcomes

  1. Time to Spontaneous Stone Passage (Distal Stones)

    Time to stone passage for distally-located stones is assessed by entries in subject diaries.

    Time frame: 4 weeks

  2. Outpatient Narcotic Analgesic Use for Pain Relief

    Narcotic analgesic use was assessed through a subject diary. Analysis was performed on the number of days with analgesic use.

    Time frame: 4 weeks

  3. Change From Baseline in Average Score on the Brief Pain Inventory (Distal Stones)

    At each study visit, subjects were given a Brief Pain Inventory (BPI) Questionnaire to complete. The BPI collects subject-reported pain severity scores and assesses impact of pain upon the subject's daily life, on a 10-point scale (with 10 being the greatest severity/impact). Analysis was change from baseline to week 4.

    Time frame: 4 weeks

  4. Time to Spontaneous Stone Passage (All Stones)

    Time to stone passage for all ureteral stones (regardless of location) is assessed by entries in subject diaries.

    Time frame: 4 weeks

07

Results

Posted Aug 11, 2014

Participant flow

Participant flow — Overall Study
MilestoneSilodsosinPlacebo
Started119120
Completed108106
Not completed1114

Outcome measures

PrimarySpontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.

The primary efficacy variable is the occurrence of spontaneous distal stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes only those stones located in the distal ureter.

Time frame:
4 weeks
Reported as:
Number · participants
Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.
participantsSilodsosinPlacebo
Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.3627
SecondaryTime to Spontaneous Stone Passage (Distal Stones)

Time to stone passage for distally-located stones is assessed by entries in subject diaries.

Time frame:
4 weeks
Reported as:
Mean · days
Time to Spontaneous Stone Passage (Distal Stones)
daysSilodsosinPlacebo
Time to Spontaneous Stone Passage (Distal Stones)19.6 ± 1.6122.0 ± 1.47
SecondaryOutpatient Narcotic Analgesic Use for Pain Relief

Narcotic analgesic use was assessed through a subject diary. Analysis was performed on the number of days with analgesic use.

Time frame:
4 weeks
Reported as:
Mean · Days
Outpatient Narcotic Analgesic Use for Pain Relief
DaysSilodsosinPlacebo
Outpatient Narcotic Analgesic Use for Pain Relief5.8 ± 8.05.5 ± 6.8
SecondaryChange From Baseline in Average Score on the Brief Pain Inventory (Distal Stones)

At each study visit, subjects were given a Brief Pain Inventory (BPI) Questionnaire to complete. The BPI collects subject-reported pain severity scores and assesses impact of pain upon the subject's daily life, on a 10-point scale (with 10 being the greatest severity/impact). Analysis was change from baseline to week 4.

Time frame:
4 weeks
Reported as:
Mean · units on a scale
Change From Baseline in Average Score on the Brief Pain Inventory (Distal Stones)
units on a scaleSilodsosinPlacebo
Change From Baseline in Average Score on the Brief Pain Inventory (Distal Stones)-2.6 ± 2.5-1.9 ± 3.1
PrimarySpontaneous Stone Passage (All Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.

The primary efficacy variable is the occurrence of spontaneous stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes all ureteral stones, regardless of location in the ureter.

Time frame:
4 weeks
Reported as:
Number · participants
Spontaneous Stone Passage (All Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.
participantsSilodsosinPlacebo
Spontaneous Stone Passage (All Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.6052
SecondaryTime to Spontaneous Stone Passage (All Stones)

Time to stone passage for all ureteral stones (regardless of location) is assessed by entries in subject diaries.

Time frame:
4 weeks
Reported as:
Mean · days
Time to Spontaneous Stone Passage (All Stones)
daysSilodsosinPlacebo
Time to Spontaneous Stone Passage (All Stones)22.3 ± 1.0222.9 ± 1.00

Adverse events

Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Silodsosin—2/119 (1.7%)27/119 (22.7%)
Placebo—2/120 (1.7%)8/120 (6.7%)
Most frequent serious events
Most frequent serious events
EventSilodsosinPlacebo
Renal colicRenal and urinary disorders2/1192/120
Most frequent other events
Most frequent other events
EventSilodsosinPlacebo
Retrograde ejaculationReproductive system and breast disorders11/1191/120
NauseaGastrointestinal disorders9/1192/120
DizzinessNervous system disorders8/1192/120
HeadacheNervous system disorders4/1190/120
VomitingGastrointestinal disorders4/1194/120

Baseline characteristics

Age, Continuous
Age, Continuous(years)SilodsosinPlaceboTotal
Mean47.4 ± 12.546.7 ± 15.247.0 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)SilodsosinPlaceboTotal
Female473683
Male7284156
08

Study locations

27 sites
  • Watson Investigational Site
    Birmingham, Alabama, United States
  • Watson Investigational Site
    Anchorage, Alaska, United States
  • Watson Investigative Site
    Mission Hills, California, United States
  • Watson Investigational Site
    Murrieta, California, United States
  • Watson Investigational Site
    San Diego, California, United States
  • Watson Investigational Site
    Daytona Beach, Florida, United States
  • Watson Investigational Site
    Gainesville, Florida, United States
  • Watson Investigational Site
    Orange City, Florida, United States
  • Watson Investigative Site
    Overland Park, Kansas, United States
  • Watson Investigative Site
    North Kansas City, Missouri, United States
  • Watson Investigational Site
    Hackensack, New Jersey, United States
  • Watson Investigational Site
    Mt Laurel, New Jersey, United States
  • Watson Investigational Site
    Sewell, New Jersey, United States
  • Watson Investigational Site
    Voorhees, New Jersey, United States
  • Watson Investigational Site
    Albany, New York, United States
  • Watson Investigational Site
    Garden City, New York, United States
  • Watson Investigational Site
    New York, New York, United States
  • Watson Investigational Site
    Plainview, New York, United States
  • Watson Investigational Site
    Syracuse, New York, United States
  • Watson Investigational Site
    Cincinnati, Ohio, United States
  • Watson Investigational Site
    Columbus, Ohio, United States
  • Watson Investigational Site
    Bala Cynwyd, Pennsylvania, United States
  • Watson Investigational Site
    Lancaster, Pennsylvania, United States
  • Watson Investigational Site
    Myrtle Beach, South Carolina, United States
  • Watson Investigational Site
    Dallas, Texas, United States
  • Watson Investigational Site
    San Antonio, Texas, United States
  • Watson Investigational Site
    Virginia Beach, Virginia, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2010
First posted
Jun 16, 2010
Start
Jun 2010
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Aug 11, 2014
Last update
Aug 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01144949
Responsible party
Sponsor
First posted
Jun 16, 2010
Start date
Jun 2010
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Aug 11, 2014
Last update
Aug 11, 2014

Study contacts

Scott Olsen, MPH
study director · Watson Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion